Related Experiment Videos
Mechanisms modifying atherosclerotic disease - from lipids to vascular biology
1Department of Medicine, Addenbrooke's Hospital, Cambridge, UK.
Insights
Statins significantly reduce cardiovascular events by altering plaque composition, not size. This highlights the importance of plaque stability over plaque volume in preventing acute coronary events.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Atherosclerosis Research
Background:
- Clinical trials show statins reduce acute coronary events, often caused by plaque rupture.
- Angiographic studies indicate statins minimally impact pre-existing plaque size.
Purpose of the Study:
- To investigate the mechanism behind statin-induced reduction in acute coronary events.
- To determine whether plaque composition or size is more critical for clinical outcomes.
Main Methods:
- Review of recent clinical trials and angiographic studies on statin efficacy.
- Analysis of atherosclerotic plaque composition, focusing on smooth muscle cells (SMCs) and inflammatory cells (macrophages).
Main Results:
- Statins' protective effects are primarily mediated by changes in plaque composition, not plaque size reduction.
- SMCs contribute to plaque stability by forming fibrous caps, while macrophages promote instability.
- Statins may improve plaque stability by reducing inflammation or promoting SMC-mediated repair.
Conclusions:
- Plaque composition is more critical than plaque size in determining cardiovascular event risk.
- The benefits of statins are not solely predicted by lipid-lowering effects; outcome trial evidence is crucial for prescription.
- Statins may influence the balance between plaque instability (inflammation) and stability (SMC repair).
Abstract:
Recent clinical trials of three statins, pravastain, simvastatin and lovastatin, have demonstrated a major reduction in acute coronary events typically precipitated by plaque rupture. However, angiographic studies with several statins have shown that they do not appear to greatly affect the size of pre-existing plaques. These findings strongly suggest that the demonstrated protective effect of these statins is mediated through changes in plaque composition rather than size, highlighting the greater importance of composition than size in determining clinical outcome. Atherosclerotic plaques are composed of a thrombogenic lipid-rich core protected by a fibrous cap comprising smooth muscle cells (SMCs) and inflammatory cells, predominantly macrophages. SMCs are the only cell type in the atherosclerotic plaque capable of synthesizing a strong fibrous cap. Their survival is therefore crucial to plaque stability. In contrast, inflammatory cells such as macrophages increase the risk of plaque rupture by a number of mechanisms. Thus, in atherosclerosis, there is a balance between the influence of inflammatory cells tending towards plaque instability and the reparative influence of SMCs tending to plaque stability. The implication of the successful outcome studies is that the statins tested may beneficially influence this balance either by decreasing inflammation or promoting repair or both. However, because statins do not have a uniform effect on all the biological processes contributing to plaque rupture and subsequent thrombosis, the potential benefit from treating with a statin cannot necessarily be presumed or predicted from its lipid lowering potency alone. Therefore prescription of statins to prevent cardiovascular events should be based on the evidence of outcome trials.